Reports Q3 revenue $95.8M, consensus $94.76M. “We continued our strong financial performance through Q3 as our team delivered revenue growth consistent with our expectations while executing on several initiatives designed to drive long-term profitable growth with our expanding, clinically differentiated product portfolio. Revenue growth in Q3 was driven by year-over-year growth in On-X of 15%, BioGlue of 14% and stent grafts of 12%, all compared to the third quarter of 2023. On a constant currency basis, year-over-year On-X, BioGlue, and stent grafts grew 15%, 14% and 13%, respectively. We also saw continued revenue strength across Asia Pacific and Latin America which grew 23% and 21%, respectively, and on a constant currency basis, 23% and 32%, compared to last year,” said CEO Pat Mackin. “We also achieved important milestones in our R&D pipeline this quarter…”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AORT:
- Artivion Inc. (AORT) Q3 Earnings Cheat Sheet
- Artivion initiated with an Outperform at JMP Securities
- Artivion management to meet with Oppenheimer
- Artivion price target raised to $30 from $28 at Stifel
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
